Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
BlackRock Health Sciences Opps R BHSRX
- NAV / 1-Day Return 68.34 / +0.21 %
- Total Assets 8.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.460%
- Distribution Fee Level Average
- Share Class Type Retirement, Medium
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 100
- Status Open
- TTM Yield 0.00
- Turnover 27%
USD | NAV as of Oct 05, 2024 | 1-Day Return as of Oct 05, 2024, 1:01 AM GMT+0
Morningstar’s Analysis BHSRX
Will BHSRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
UnitedHealth Group Inc | 9.27 | 810.5 Mil | Healthcare |
Eli Lilly and Co | 8.20 | 716.6 Mil | Healthcare |
Boston Scientific Corp | 5.73 | 500.6 Mil | Healthcare |
Amgen Inc | 3.94 | 344.2 Mil | Healthcare |
Thermo Fisher Scientific Inc | 3.64 | 318.2 Mil | Healthcare |
Intuitive Surgical Inc | 3.42 | 299.2 Mil | Healthcare |
Danaher Corp | 3.35 | 292.9 Mil | Healthcare |
AbbVie Inc | 3.35 | 292.8 Mil | Healthcare |
Elevance Health Inc | 2.99 | 261.2 Mil | Healthcare |
Stryker Corp | 2.77 | 242.3 Mil | Healthcare |